The Introduction of a Novel PAOO Technique

Launched by SEMMELWEIS UNIVERSITY · Mar 2, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new technique called preorthodontic piezotomy, combined with a procedure to rebuild bone, to see if it can help prevent gum recession and speed up tooth movement during orthodontic treatment. The researchers want to find out if this approach can make braces work better for patients who have crowded teeth and thin bone around their teeth.

To participate, individuals should be between the ages of 18 and 65 and have a specific type of tooth crowding where there isn’t enough space for the teeth. They should also have thin bone around their teeth, which can make orthodontic treatment more challenging. However, certain health conditions or treatments, like ongoing gum disease, pregnancy, or recent serious illnesses, may prevent someone from joining the trial. If eligible, participants can expect to receive treatment and be monitored closely throughout the study to assess how effective this new technique is.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • tooth crowding exceeding a 5mm lack of space (originating from the discrepancy between the overall mesiodostal length of the teeth and the length of the dental arch present at the time of the evaluation)
• • thin bone morphotype (buccal width of the cortical layer must be under 1mm)
• • incisor proclination in order to eliminate crowding without compensatory extractions.
• • informed consent
• Exclusion Criteria:
• • ongoing periodontitis
• • Pregnant women.
• • Participation in another clinical study within 30 days prior to study start.
• • Alcoholism, drug dependency, heavy smoking (\>5 cigarettes/day).
• • Known infection with HIV, HBV, or HCV.
• • Patients requiring chemo- or radiotherapy.
• • Previous or current radiotherapy of the head.
• • Uncontrolled or insulin-dependent diabetes mellitus
• • Clinically relevant osteoporosis or systemic disease affecting bone metabolism
• • Clinically relevant cardiovascular disease e.g., decompensated cardiac insufficiency, hemodynamically relevant heart valve defects, or myocardial infarction during the last three months.
• • Clinically relevant blood coagulation disorder.
• • Previous or current treatment with systemic corticosteroids (within 2 months prior to screening visit) of more than 5 mg/day prednisone equivalent.
• • Previous or current therapy with bisphosphonates at least for 30 days within the last 12 months before screening visit